← Back
Data updated: Mar 10, 2026
HANGZHOU BINJIANG
Cardiovascular
HANGZHOU BINJIANG is a generic drug manufacturer focused on Cardiovascular.
2009
Since
4
Drugs
-
Trials
22
Approved (2yr)
Recent Activity
ALENDRONATE SODIUM 2026-02-03
Labeling
ALENDRONATE SODIUM 2026-02-03
Labeling
ALENDRONATE SODIUM 2026-01-28
Labeling
ALENDRONATE SODIUM 2026-01-28
Labeling
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE 2025-10-10
Labeling
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE 2025-09-30
Labeling
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE 2025-09-30
Labeling
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE 2025-09-26
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE 2025-08-20
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE 2025-08-01
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 100%
1 drugs
Pipeline Strength Pro
Loading...
Discontinued (1)
Company Info
- First Approval
- 2009-09-24
- Latest
- 2025-08-20
- Applications
- 4